TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

Breast Cancer Clinical Trial

— TACTIC  

Official title:

Tumor Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03093350
• Other study ID #: H-39209 TACTIC
• Secondary ID: P50CA186784
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 10, 2017
• Est. completion date: May 30, 2024

Study information

• Verified date: June 2023
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Status - CLOSED TO PATIENT ENROLLMENT (CNPE)

The study is being conducted in patients in which breast cancer has come back after standard treatment. Volunteers in this research study are treated using special immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.

The proteins that investigators are targeting in this study are called tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They do not show, or they show up in low quantities, on normal human cells. In this study, investigators target five common TAAs. They are called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX2. On a different study, patients have been treated and so far this treatment has shown to be safe.

Investigators now want to try this treatment in patients with breast cancer.

These TAA-specific cytotoxic T lymphocytes (TAA-CTLs) are an investigational product not approved by the Food and Drug Administration.

The purpose of this study is to determine the clinical efficacy of TAA-specific CTLs, to learn what the side-effects are, and to see whether this therapy might help patients with breast cancer.

Description:

Status - CLOSED TO PATIENT ENROLLMENT (CNPE)

Investigators will take a maximum of approximately 79 teaspoons of blood from patients on one to three occasions over a two-month period. Under certain conditions related to the patient's health, blood may be collected using a process called apheresis. Apheresis is the process where blood is passed through a machine that separates out the components of blood that we need. The remainder of the patient's blood will then be returned to his/her body.

Investigators will use this blood to grow T cells. Investigators will first grow a special type of cells called dendritic cells which will activate T cells. Once these are made, investigators will load them with small pieces of protein called peptides taken from the TAAs that we want to target. This helps train the T cells to kill cancer cells which express TAAs on their surface. Then the TAA-specific CTLs are expanded.

The cells will be infused by intravenous infusion (IV) into the patient over 1-10 minutes. The patient may be pre-treated with acetaminophen (Tylenol) and diphenhydramine (Benadryl). Acetaminophen (Tylenol) and diphenhydramine (Benadryl) are given to prevent a possible allergic reaction to the TAA-CTL administration. Initially, two doses of TAA-CTLs will be given four weeks apart. The patient's cancer will be assessed pre-infusion, and then 6 weeks after the second infusion. If after the second infusion there is a reduction in the size of the patient's tumor on Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or Positron Emission Tomography (PET) as assessed by a radiologist, the patient can receive up to six (6) additional doses of the TAA-CTLs if they wish. At least one month should pass before each additional dose. All of the treatments will be given by the Center for Cell and Gene Therapy at Houston Methodist Hospital.

In between the first and second TAA-CTL infusions, and for 6 weeks after the 2nd infusion, the patient should not receive any other anti-cancer treatments such as radiation therapy or chemotherapy. If the patient does receive any other therapies in-between the first and second infusion of TAA-CTLs, they will be taken off treatment and will not be able to receive the second infusion.

MEDICAL TESTS BEFORE TREATMENT:

Before being treated, patients will receive a series of standard medical tests:

• Physical exam.

• Blood tests to measure blood cells, kidney and liver function.

• Measurements of the patient's tumor by routine imaging studies.

• Pregnancy test if the patient is a female who can have children.

MEDICAL TESTS DURING TREATMENT:

Patients will receive standard medical tests on the day of their second and subsequent infusions:

• Physical exam

• Blood tests to measure blood cells, kidney and liver function.

MEDICAL TESTS AFTER TREATMENT

• Imaging study 6 weeks after the 2nd TAA-CTL infusion.

To learn more about the way the TAA-CTLs are working in the patient's body, an extra 20-40 mL (4-8 teaspoons) of blood will be taken before each infusion, at Weeks 1, 2, and 4 after the first cell dose and at Weeks 1, 2, 4 and 6 after the second cell dose. Afterwards, blood will be collected at 3, 6, 9 and 12 months after the 2nd infusion. Investigators will use this blood to see how long the TAA-CTLs last, and to look at the patient's immune system response to the cancer. The immune system is part of the body that helps protect against disease.

Study Duration: The patient's active participation in this study will last for approximately one (1) year. If the patient receives additional doses of the TAA-CTLs as described above, his/her active participation will last until one (1) year after the last dose. Investigators will then contact the patient once a year for up to 4 additional years (total of 5 years follow-up) in order to evaluate the patient's disease response long-term.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 12
• Est. completion date: May 30, 2024
• Est. primary completion date: May 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Status - CLOSED TO PATIENT ENROLLMENT (CNPE)

PROCUREMENT INCLUSION CRITERIA:

1. Any breast cancer patient with metastatic or locally recurrent unresectable disease.

2. Patients with life expectancy greater than or equal to 12 weeks.

3. Age greater than or equal to 18 and less than or equal to 80 years old.

4. Hgb greater than or equal to 7.0.

5. Informed Consent explained to, understood by and signed by patient. Patient given copy of informed consent.

TREATMENT INCLUSION CRITERIA:

1. Any breast cancer patient with metastatic or locally recurrent unresectable breast cancer currently progressive, after at least two prior lines of therapy in the advanced setting. Patients with HER2+ disease must have failed two or more different anti-HER2 agents.

2. Patients must have measurable or evaluable disease per RECIST 1.1 criteria.

3. Patients with life expectancy greater than or equal to 12 weeks.

4. Age greater than or equal to 18 and less than or equal to 80 years old.

5. Pulse oximetry of greater than 95% on room air.

6. Patients with ECOG score less than or equal to 2 or a Karnofsky score of greater than or equal to 50.

7. Patients with bilirubin less than or equal to 2x upper limit of normal, AST less than or equal to 3x upper limit of normal, and Hgb greater than or equal to 7.0.

8. Patients with a creatinine normal for age.

9. Patients should have been off other investigational therapy for one month prior to receiving treatment on this study.

10. Patients should have been off conventional therapy for at least 1 week prior to receiving treatment on this study.

11. Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion.

12. Informed Consent explained to, understood by and signed by patient. Patient given copy of informed consent.

PROCUREMENT EXCLUSION CRITERIA:

1. Patients with severe intercurrent infection.

2. Patients with active HIV infection at time of procurement.

3. Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation.

TREATMENT EXCLUSION CRITERIA:

1. Patients with severe intercurrent infection.

2. Patients receiving systemic corticosteroids (Patients off steroids for at least 48 hours are eligible).

3. Pregnant or lactating.

4. Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation.

5. HIV positive.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Biological:
• TAA-specific CTLs
Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc. Dose schedule: Day 0: 2 x 10^7 cells/m2 Day 28: 2 x 10^7 cells/m2 If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.

Locations

Country	Name	City	State
United States	Houston Methodist Hospital	Houston	Texas
United States	Smith Clinic - Harris Health System	Houston	Texas

Sponsors (5)

Lead Sponsor	Collaborator
Baylor College of Medicine	Cancer Prevention Research Institute of Texas, Center for Cell and Gene Therapy, Baylor College of Medicine, National Cancer Institute (NCI), The Methodist Hospital Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Evaluable Patients With Complete Response or Partial Response or Stable Disease for =10 Weeks From the First Infusion (6 Weeks After the Second Infusion) According to the RECIST Criteria	To determine the clinical efficacy associated with the administration of multiTAA-specific T cells in breast cancer patients with metastatic or locally recurrent unresectable disease as measured by clinical benefit rate (defined as overall response plus stable disease for 10 weeks or longer). Per the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria and assessed by CT or MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions; Progressive Disease (PD), At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started; Overall Response (OR) = CR + PR.	12 weeks
Secondary	Median Progression-free Survival	To evaluate the progression-free survival of patients after multiTAA-specific T cell infusion. Progression is defined, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) Criteria, as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.	1 year
Secondary	Median Overall Survival	To evaluate the overall survival of patients after multiTAA-specific T cell infusion	1 year